IL6 and COVID-19: For instance, Betts and colleagues reviewed evidence supporting ruxolitinib, an interleukin-6 blocker, concluding that, “the rationale to test its use in treating patients with severe or very severe COVID-19 illness merits at least equipoise or serious reconsideration,” and that “disciplined clinical research” is justified [5].